Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannabis PolandFRA:8TE +2.27%26 PB Ratio is 1.73 as of Jul. 14, 2026, which is 75% below its 10-year median of 6.93. GuruFocus rates FRA:8TE with a GF Score™ of 26/100 and a GF Value™ of €0.02 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 921 Drug Manufacturers companies, Cannabis Poland ranks worse than 71.55% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-14), Cannabis Poland's share price is €0.0225. Cannabis Poland's Book Value per Share for the quarter that ended in Mar. 2026 was €0.01. Hence, Cannabis Poland's PB Ratio of today is 1.73.
Good Sign:
Cannabis Poland SA stock PB Ratio (=3.33) is close to 5-year low of 3.07.
The historical rank and industry rank for Cannabis Poland's PB Ratio or its related term are showing as below:
FRA:8TE'
s PB Ratio Range Over the Past 10 Years
Min: 0.48 Med: 6.93 Max: 220.48
Current: 3.33
During the past 13 years, Cannabis Poland's highest PB Ratio was 220.48. The lowest was 0.48. And the median was 6.93.
FRA:8TE's PB Ratio is ranked worse than 71.55% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs FRA:8TE: 3.33
During the past 12 months, Cannabis Poland's average Book Value Per Share Growth Rate was 12.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -13.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cannabis Poland was 146.60% per year. The lowest was -83.30% per year. And the median was 4.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cannabis Poland PB Ratio Related Terms
Cannabis Poland PB Ratio Historical Data
* Premium members only.
The historical data trend for Cannabis Poland's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Poland's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Poland PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannabis Poland's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cannabis Poland's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cannabis Poland's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cannabis Poland (FRA:8TE) has a PB Ratio of 1.73 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cannabis Poland and its competitors. This is 75% below median its historical median of 6.93. Over the past decade, Cannabis Poland's PB Ratio has ranged from 0.48 to 220.48. According to the industry distribution chart, Cannabis Poland ranks #659 out of 921 companies in the Drug Manufacturers industry, placing it in the top 71.6%.
Is Cannabis Poland's PB Ratio too high?
Cannabis Poland's current PB Ratio of 1.73 is 75% below median its 10-year median of 6.93. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 220.48. The Drug Manufacturers industry median PB Ratio is 1.90. Cannabis Poland's value of 1.73 is 8.9% below this industry median. Based on the distribution chart, Cannabis Poland ranks #659 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cannabis Poland has a GF Score™ of 26/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannabis Poland's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannabis Poland ranks #659 out of 921 companies for PB Ratio. This places Cannabis Poland in the lower half of its industry. The industry median PB Ratio is 1.90. Cannabis Poland's value of 1.73 is 8.9% below this benchmark. Historically, Cannabis Poland's own PB Ratio has ranged from 0.48 to 220.48 over the past decade. While the company's 10-year median is 6.93 vs. the industry median of 1.90, Cannabis Poland has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabis Poland's current PB Ratio of 1.73 is 8.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cannabis Poland and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Poland's current PB Ratio is 1.73, which is 75% below median its own 10-year median of 6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Poland stock overvalued right now?
Based on GuruFocus' analysis, Cannabis Poland (FRA:8TE) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.02, compared to a current price of €0.02 — trading 12.5% above its estimated fair value. The current PB Ratio is 1.73, which is 75% below median its 10-year median of 6.93 and 8.9% below the Drug Manufacturers industry median of 1.90. Cannabis Poland's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cannabis Poland (FRA:8TE), the current PB Ratio is 1.73 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannabis Poland (FRA:8TE) Overvalued in 2026?
Based on GuruFocus' analysis, Cannabis Poland stock appears to be overvalued.
The current stock price of €0.02 is trading 12.5% above its estimated GF Value™ of €0.02.
GuruFocus considers Cannabis Poland to be Modestly Overvalued.
Key valuation signals for FRA:8TE:
PB Ratio: 1.73 (75% below median its 10-year median of 6.93)
GF Value™: €0.02 vs. price of €0.02 (12.5% above fair value)
Industry Position: 8.9% below the Drug Manufacturers median (#659 of 921)
No single metric tells the full story. See the FRA:8TE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8TE has been successfully added to your 
